Russian version English version
About the Journal
Editorial Board
Instructions for Authors
Information for Readers and Authors
Current Issue
Archive
Contact Us
Search

Send manuscript
 


Volume 17   Issue 2   Year 2022
References

  1. Tahbaz R., Schmid M., Merseburger A.S. Prevention of kidney cancer incidence and recurrence: lifestyle, medication and nutrition. Curr. Opin. Urol. 2018;28(1):62–79. doi: 10.1097/MOU.0000000000000454
  2. Gomella P.T., Linehan W.M., Ball M.W. Precision surgery and kidney cancer: knowledge of genetic alterations influences surgical management. Genes. 2021;12(2):261. doi: 10.3390/genes12020261
  3. Capitanio U., Bensalah K., Bex A., Boorjian S.A., Bray F., Coleman J., Gore J.L., Sun M., Wood C., Russo P. Epidemiology of renal cell carcinoma. European Urology. 2019;75(1):74–84. doi: 10.1016/j.eururo.2018.08.036
  4. Linehan W.M., Schmidt L.S., Crooks D.R., Wei D., Srinivasan R., Lang M., Ricketts C.J. The Metabolic Basis of Kidney CancerThe Metabolic Basis of Kidney Cancer. Cancer Discovery. 2019;9(8):1006–1021. doi: 10.1158/2159-8290.CD-18-1354
  5. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021;71(3):209–249. doi: 10.3322/caac.21660
  6. Wolf M.M., Kimryn Rathmell W., Beckermann K.E. Modeling clear cell renal cell carcinoma and therapeutic implications. Oncogene. 2020;39:3413–3426. doi: 10.1038/s41388-020-1234-3
  7. Hsieh J.J., Purdue M.P., Signoretti S., Swanton C., Albiges L., Schmidinger M., Heng D.Y, Larkin J., Ficarra V. Renal cell carcinoma. Nat. Rev. Dis. Primers. 2017;3:17009. doi: 10.1038/nrdp.2017.9
  8. Eliasson L., Regazzi R. Micro(RNA) management and mismanagement of the islet. Journal of Molecular Biology. 2020;432(5):1419–1428. doi: 10.1016/j.jmb.2019.09.017
  9. Budakoti M., Panwar A.S., Molpa D., Singh R.K., Büsselberg D., Mishra A.P., Coutinho H.D., Nigam M. Micro-RNA: The darkhorse of cancer. Cellular Signalling. 2021;83:109995. doi: 10.1016/j.cellsig.2021.109995
  10. Weidle U.H., Nopora A. Clear Cell Renal Carcinoma: MicroRNAs With Efficacy in Preclinical In Vivo Models. Cancer Genomics & Proteomics. 2021;18(3 Suppl):349–368. doi: 10.21873/cgp.20265
  11. Huang Y.X., Nie X.G., Li G.D., Fan D.S., Song L.L., Zhang X.L. Downregulation of microRNA 182 inhibits cell viability, invasion and angiogenesis in retinoblastoma through inhibition of the PI3K/AKT pathway and CADM2 upregulation. International Journal of Oncology. 2018;53(6):2615–2626. doi: 10.3892/ijo.2018.4587
  12. Ullah R., Naz A., Akram H.S., Ullah Z., Tariq M., Mithani A., Faisal A. Transcriptomic analysis reveals differential gene expression, alternative splicing, and novel exons during mouse trophoblast stem cell differentiation. Stem Cell Research & Therapy. 2020;11:342. doi: 10.1186/s13287-020-01848-8
  13. Rostovskaya M., Andrews S., Reik W., Rugg-Gunn P.J. Amniogenesis occurs in two independent waves in primates. Cell Stem Cell. 2022;29(5):744–759. doi: 10.1016/j.stem.2022.03.014
  14. Chen S.C., Kuo P.L. Bone metastasis from renal cell carcinoma. International Journal of Molecular Sciences. 2016;17(6):987. doi: 10.3390/ijms17060987
  15. Liu F., Tang Y., Guo Q., Chen J. Identification and characterization of microRNAs in phloem and xylem from ramie (Boehmeria nivea). Molecular Biology Reports. 2020;47:1013–1020. doi: 10.1007/s11033-019-05193-9
  16. Kozomara A., Birgaoanu M., Griffiths-Jones S. miRBase: from microRNA sequences to function. Nucleic Acids Research. 2019;47(D1):D155–D162. doi: 10.1093/nar/gky1141
  17. Love M.I., Huber W., Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biology. 2014;15:550. doi: 10.1186/s13059-014-0550-8
  18. Garcia-Moreno A., López-Domínguez R., Villatoro-García J.A., Ramirez-Mena A., Aparicio-Puerta E., Hackenberg M., Pascual-Montano A., Carmona-Saez P. Functional Enrichment Analysis of Regulatory Elements. Biomedicines. 2022;10(3):590. doi: 10.3390/biomedicines10030590
  19. Huang C., Li J., Zhang X., Xiong T., Ye J., Yu J., Gui Y. The miR‐140‐5p/KLF9/KCNQ1 axis promotes the progression of renal cell carcinoma. The FASEB Journal. 2020;34:10623–10639. doi: 10.1096/fj.202000088RR
  20. Bai Y., Li H., Dong J. Up-regulation of miR-20a weakens inflammation and apoptosis in high-glucose-induced renal tubular cell mediating diabetic kidney disease by repressing CXCL8 expression. Archives of Physiology and Biochemistry. 2022;128(6):1603–1610. doi: 10.1080/13813455.2020.1785506
  21. Carlsson J., Christiansen J., Davidsson S., Giunchi F., Fiorentino M., Sundqvist P. The potential role of miR 126, miR 21 and miR 10b as prognostic biomarkers in renal cell carcinoma. Oncology Letters. 2019;17(5):4566–4574. doi: 10.3892/ol.2019.10142
  22. Chi X.G., Meng X.X., Ding D.L., Xuan X.H., Chen Y.Z., Cai Q., Wang A. HMGA1-mediated miR-671-5p targets APC to promote metastasis of clear cell renal cell carcinoma through Wnt signaling. Neoplasma. 2020;67(1):46–53. doi: 10.4149/neo_2019_190217N135
  23. Hell M.P., Thoma C.R., Fankhauser N., Christinat Y., Weber T.C., Krek W. miR-28-5p Promotes Chromosomal Instability in VHL-Associated Cancers by Inhibiting Mad2 TranslationpVHL Controls Aneuploidy via miR-28-5p. Cancer Research. 2014;74(9):2432–2443. doi: 10.1158/0008-5472.CAN-13-2041
  24. Morais M., Dias F., Nogueira I., Leão A., Gonçalves N., Araújo L., Granja S., Baltazar F., Teixeira A.L., Medeiros R. Cancer cells’ metabolism dynamics in renal cell carcinoma patients’ outcome: influence of GLUT-1-Related hsa-miR-144 and hsa-miR-186. Cancers. 2021;13(7):1733. doi: 10.3390/cancers13071733
  25. Wang P., Zhao F., Nie X., Liu J., Yu Z. Knockdown of NUP160 inhibits cell proliferation, induces apoptosis, autophagy and cell migration, and alters the expression and localization of podocyte associated molecules in mouse podocytes. Gene. 2018;664:12–21. doi: 10.1016/j.gene.2018.04.067
  26. Chu C.A., Lee C.T., Lee J.C., Wang Y.W., Huang C.T., Lan S.H., Lin P.C., Lin B.W., Tian Y.F., Liu H.S. et al. MiR-338-5p promotes metastasis of colorectal cancer by inhibition of phosphatidylinositol 3-kinase, catalytic subunit type 3-mediated autophagy pathway. eBioMedicine. 2019;43:270–281. doi: 10.1016/j.ebiom.2019.04.010
  27. Block I., Burton M., Sørensen K.P., Andersen L., Larsen M.J., Bak M., Cold S., Thomassen M., Tan Q., Kruse T.A. Association of miR-548c-5p, miR-7-5p, miR-210-3p, miR-128-3p with recurrence in systemically untreated breast cancer. Oncotarget. 2018;9:9030–9042. doi: 10.18632/oncotarget.24088
  28. Zhang Y., Huo W., Sun L., Wu J., Zhang C., Wang H., Wang B., Wei J., Qu C., Cao H. et al. Targeting miR-148b-5p Inhibits Immunity Microenvironment and Gastric Cancer Progression. Frontiers in Immunology. 2021;12:590447. doi: 10.3389/fimmu.2021.590447
  29. Richardsen E., Andersen S., Al-Saad S., Rakaee M., Nordby Y., Pedersen M.I., Ness N., Ingebriktsen L.M., Fassina A., Tasken K.A. et al. Low expression of miR-424-3p is highly correlated with clinical failure in prostate cancer. Scientific Reports. 2019;9:10662. doi: 10.1038/s41598-019-47234-0
  30. Fang R., Huang Y., Xie J., Zhang J., Ji X. Downregulation of miR-29c-3p is associated with a poor prognosis in patients with laryngeal squamous cell carcinoma. Diagnostic Pathology. 2019;14:109. doi: 10.1186/s13000-019-0893-2
  31. Wu Y., Bi Q.J., Han R., Zhang Y. Long noncoding RNA KCNQ1OT1 is correlated with human breast cancer cell development through inverse regulation of hsa-miR-107. Biochemistry and Cell Biology. 2020;98(3):338–344. doi: 10.1139/bcb-2019-0271
  32. He R.Q., Wu P.R., Xiang X.L., Yang X., Liang H.W., Qiu X.H., Yang L.H., Peng Z.G., Chen G. Downregulated miR-23b-3p expression acts as a predictor of hepatocellular carcinoma progression: A study based on public data and RT-qPCR verification. International Journal of Molecular Medicine. 2018;41(5):2813–2831. doi: 10.3892/ijmm.2018.3513
  33. Liu C., Barger C.J., Karpf A.R. Foxm1: A multifunctional oncoprotein and emerging therapeutic target in ovarian cancer. Cancers. 2021;13(12):3065. doi: 10.3390/cancers13123065
  34. Yang X., Yang S., Song J., Yang W., Ji Y., Zhang F., Rao J. Dysregulation of miR-23b-5p promotes cell proliferation via targeting FOXM1 in hepatocellular carcinoma. Cell Death Discovery. 2021;7:47. doi: 10.1038/s41420-021-00440-0
  35. Zhao L., Jiang P., Zheng H., Chen P., Yang M. Downregulation of miR-499a-5p predicts a poor prognosis of patients with non-small cell lung cancer and restrains the tumorigenesis by targeting fibroblast growth factor 9. Technology in Cancer Research & Treatment. 2020;19:1533033820957001. doi: 10.1177/1533033820957001
  36. Zhao L., Li R., Xu S., Li Y., Zhao P., Dong W., Liu Z., Zhao Q., Tan B. Tumor suppressor miR-128-3p inhibits metastasis and epithelial–mesenchymal transition by targeting ZEB1 in esophageal squamous-cell cancer. Acta Biochimica et Biophysica Sinica. 2018;50(2):171–180. doi: 10.1093/abbs/gmx132
  37. Lukamowicz-Rajska M., Mittmann C., Prummer M., Zhong Q., Bedke J., Hennenlotter J., Stenzl A., Mischo A., Bihr S., Schmidinger M. et al. MiR-99b-5p expression and response to tyrosine kinase inhibitor treatment in clear cell renal cell carcinoma patients. Oncotarget. 2016;7:78433–78447. doi: 10.18632/oncotarget.12618
  38. Zhang H., Zheng H., Mu W., He Z., Yang B., Ji Y., Hui L. DUSP 16 ablation arrests the cell cycle and induces cellular senescence. The FEBS Journal. 2015;282(23):4580–4594. doi: 10.1111/febs.13518
  39. Wei X., Li H., Zhang B., Li C., Dong D., Lan X., Huang Y., Bai Y., Lin F., Zhao X. et al. miR-378a-3p promotes differentiation and inhibits proliferation of myoblasts by targeting HDAC4 in skeletal muscle development. RNA Biology. 2016;13(12):1300-1309. doi: 10.1080/15476286.2016.1239008
  40. Qian M., Xu H., Song H., Xi H., Fang L. MiR-218-5p promotes breast cancer progression via LRIG1: preprint. Research Square. 2021. doi: 10.21203/rs.3.rs-203193/v1
  41. Wang H., Deng Q., Lv Z., Ling Y., Hou X., Chen Z., Dinglin X., Ma S., Li D., Wu Y. et al. N6-methyladenosine induced miR-143-3p promotes the brain metastasis of lung cancer via regulation of VASH1. Molecular Cancer. 2019;18:181. doi: 10.1186/s12943-019-1108-x
  42. Wang L., Ge S., Zhou F. MicroRNA-487a-3p inhibits the growth and invasiveness of oral squamous cell carcinoma by targeting PPM1A. Bioengineered. 2021;12(1):937–947. doi: 10.1080/21655979.2021.1884396
  43. Wang C., Cai L., Liu J., Wang G., Li H., Wang X., Xu W., Ren M., Feng L., Liu P. et al. MicroRNA-30a-5p inhibits the growth of renal cell carcinoma by modulating GRP78 expression. Cellular Physiology and Biochemistry. 2017;43(6):2405–2419. doi: 10.1159/000484394
  44. Liu C., Li G., Ren S., Su Z., Wang Y., Tian Y., Liu Y., Qiu Y. miR-185-3p regulates the invasion and metastasis of nasopharyngeal carcinoma by targeting WNT2B in vitro. Oncology Letters. 2017;13(4):2631–2636. doi: 10.3892/ol.2017.5778
Table of Contents
Original Article
Rana H. Hamoode, Tamadher A. Rafaa, Rafat H. Abduljaleel, Ahmed A. Suleiman Identification of Novel miRNAs Involved in Cancer Progression and Metastasis in Clear Cell Renal Cell Carcinoma. Ìàthematical biology and bioinformatics. 2022;17(2):338-359. doi: 10.17537/2022.17.338
(published in English)

Abstract (eng.)
Abstract (rus.)
Full text (eng., pdf)
References
Supplementary data

 
  Copyright IMPB RAS © 2005-2025